RIF tokens are used to fund and engage with scientific experiments exploring Rifampicin's role in extending lifespan. Through the Pump.science platform, users can:

• Propose and support longevity experiments involving Rifampicin by purchasing RIF tokens.
• Track live experimental data from studies on organisms such as C. elegans (worms), with planned expansions to flies, mice, and eventually human trials.
• Trade RIF tokens in prediction markets where the value is influenced by the success of the related experiments.
• Monetise intellectual property (IP), as token holders retain rights that could be licensed or sold to chemical suppliers for broader applications.

By gamifying the research process, RIF supports faster, cost-efficient, and community-driven scientific discovery.

Rifampicin (RIF) was launched by Pump.science, a decentralised science (DeSci) platform that integrates blockchain technology with scientific research. Pump.science operates within the broader DeSci ecosystem alongside contributors such as Molecule and BIO Protocol. These entities aim to democratise funding and innovation in scientific research, particularly focusing on longevity studies. The platform uses decentralised funding mechanisms, gamification, and community participation to address the challenges of speed, cost, and data quality in drug discovery.

Although 'RIF' was the ticker assigned at the deployment of the RIFA Token's smart contract, it is already in use by another asset that has a larger market presence and higher trading volume on major exchanges. Due to this pre-existing association and to avoid confusion in the marketplace, the alternative ticker 'RIFA' has been adopted for this token. This designation is specifically used to ensure that assets are distinctly identified.